Experimental cell injection tested to repair scarred lungs
Disease control
Completed
This study tested whether a new cell therapy called REGEND001 could help people with idiopathic pulmonary fibrosis (IPF), a serious disease that scars the lungs. In this Phase 2 trial, 23 patients were randomly assigned to receive either the cell therapy or a placebo (dummy treat…
Phase: PHASE2 • Sponsor: Regend Therapeutics • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC